Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

NCT05480657 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study withdrawn

Conditions

Brittle Type 1 Diabetes Mellitus

Interventions

BIOLOGICAL: AT-1501 IV Infusion
BIOLOGICAL: Isolated cadaveric islet cells

Sponsor

Eledon Pharmaceuticals